The report "Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care)- Global Forecast to 2031" is projected to grow from USD 0.35 billion in 2025 and to reach USD 0.35 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 35.2% during the forecast period.

Browse 250 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on "Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care)- Global Forecast to 2031"

Download PDF- https://www.marketsandmarkets.com/Market-Reports/human-microbiome-drugs-market-261309704.html

The human microbiome drugs market is significantly influenced by advances and adoption of live biotherapeutic products, next-generation probiotics, postbiotics, and microbial therapies. Rising R&D spending and clinical pipelines for metabolic, gastrointestinal, immune, and dermatological disorders are the main drivers of the rapid pace of new product introductions. The growing number of patients with chronic diseases underscores the need for awareness of gut-microbiome therapeutic modalities. Key barriers may limit market growth, including complex regulatory requirements, clinical trial design, high development costs, and specialized manufacturing needs, which can affect timelines and market growth. However, researchers are focusing on enhancing the engineering capabilities of microbial consortia, precision dosing, and encapsulation. These techniques improve safety, efficacy, and patient compliance and provide momentum to the market.

By disease, the gastrointestinal disease segment accounted for the largest share of the market in 2024.

By type, the human microbiome drugs market is divided into segments for gastrointestinal diseases, infectious diseases, and other diseases. The gastrointestinal disease segment accounted for the highest share of the Human Microbiome Drugs Market revenue in 2024. Disease indications such as irritable bowel syndrome, inflammatory bowel disease, and recurrent Clostridioides difficile infections are the most widespread, and microbiome-based therapeutic interventions are the most likely method of treatment. Industry growth is supported by research activities exploring the gut-microbiome link and the development of next-generation microbiome-based therapies. The increase in clinical research, treatment pipelines, and patient demand for non-antibiotic, microbiome-focused interventions are the main factors further facilitating growth. The segment's market leadership is strengthened by the ability of microbiome drugs to restore gut balance and improve digestive ?‍?‌‍?‍‌?‍?‌‍?‍‌health.

By end users, the hospitals & clinics segment accounted for the largest share of the market in 2024.

By end user, the human microbiome drugs market is divided into hospitals & clinics, long-term care facilities, and other end users. Hospitals and clinics garnered the largest revenue share of the Human Microbiome Drugs Market in 2024. Prominent adoption of microbiome drugs across hospitals & clinics is supported by the proven clinical significance of microbiome-based therapies, coupled with enhanced patient monitoring approaches. Strong capabilities in trained personnel, infrastructure, and patient engagement for follow-up monitoring contribute to segment growth. Moreover, they engage in clinical trials and early-access programs. The increasing prevalence of chronic diseases and the rising demand for microbiome-targeted treatments further strengthen hospitals and clinics as the foremost end users ?‍?‌‍?‍‌?‍?‌‍?‍‌segment.

By region, North America accounted for the largest share of the market in 2024.

In 2024, North America (the US and Canada) captured the largest share of revenue in the Human Microbiome Drugs Market. An expanding pool of innovative SMEs, a maturing pipeline for microbiome modalities, and a growing inclination toward live biotherapeutic products (LBPs) and next-generation microbial therapies are notable factors driving market momentum. The US is equipped with progressive regulatory frameworks, including FDA approvals and fast-track designations for microbiome drugs that target gastrointestinal, immune, and recurrent Clostridioides difficile infections. The region is also home to a large number of clinical trials, supported by academic institutions and biotech companies researching microbial consortia for metabolic, dermatological, and neurological disorders.

Market players making significant contributions to the development of the human microbiome drug industry include Seres Therapeutics (US), Ferring B.V. (Switzerland), MaaT Pharma (France), BiomeBank (Australia), Infant Bacterial Therapeutics AB (Sweden), and Finch Therapeutics Group, Inc. (US), among ?‍?‌‍?‍‌?‍?‌‍?‍‌others.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.